This experiment develops and validates a blood-based biomarker panel for early detection of Alzheimer's disease, combining multiple protein markers and machine learning for optimal diagnostic accuracy.
Primary Hypothesis: A panel of 5-7 blood biomarkers (Aβ42/40 ratio, p-tau181, p-tau217, NfL, GFAP, and IL-6) will detect preclinical AD with >90% sensitivity and >85% specificity.
Secondary Hypothesis: The biomarker panel will predict progression from MCI to AD dementia within 3 years with >80% accuracy.
Early detection of Alzheimer's disease is critical for timely intervention. Current diagnostic methods (CSF biomarkers, PET imaging) are invasive or expensive. Blood-based biomarkers offer a scalable, accessible alternative.
Key advantages:
- Minimally invasive (routine blood draw)
- Cost-effective ($50-200 vs. $3000+ for PET)
- Scalable for population screening
- Enables longitudinal monitoring
- Preclinical AD (cognitively normal, amyloid PET+): n=150
- MCI due to AD (amyloid PET+): n=150
- AD dementia: n=100
- Healthy controls (amyloid PET-): n=100
- Multi-center enrollment (10 sites)
- Independent cohort from discovery
- Longitudinal follow-up (2 years)
-
Amyloid:
- Plasma Aβ42/40 ratio (Simoa, Fujirebio)
- PrecivityAD assay (C2N Diagnostics)
-
Tau:
- p-tau181 (Simoa, Quanterix)
- p-tau217 (Simoa, Lilly)
- p-tau231 (Simoa)
-
Neurodegeneration:
-
Inflammation:
- IL-6, TNF-α, IL-1β (multiplex)
- Feature selection: LASSO regression
- Model: Random forest, XGBoost, logistic regression
- Validation: 10-fold cross-validation, external validation
- Primary: AUC for preclinical AD detection
- Secondary:
- Sensitivity, specificity at optimal threshold
- Correlation with PET biomarkers
- Predictive accuracy for progression
- Comparison with clinical criteria
¶ Reagents and Equipment
| Item |
Supplier |
Cost (USD) |
| Simoa HD-X analyzer |
Quanterix |
$50/sample |
| p-tau181 kit |
Quanterix |
$30,000 (200 tests) |
| p-tau217 kit |
Lilly |
$25,000 (200 tests) |
| NfL kit |
Quanterix |
$20,000 (200 tests) |
| GFAP kit |
Quanterix |
$20,000 (200 tests) |
| Aβ42/40 kit |
Fujirebio |
$25,000 (200 tests) |
| Cytokine multiplex |
Meso Scale Discovery |
$15,000 |
| Statistical software |
SAS/R |
$5,000 |
Estimated Total Cost: $350,000 (with assay costs)
- University of Gothenburg — Dr. Kaj Blennow's group (biomarker pioneers)
- Washington University — Dr. Randall Bateman's group (blood biomarkers)
- University of California San Francisco — Dr. Adam Boxer's group (SCIEN)
- King's College London — Dr. Abdul Hye's group (multimodal biomarkers)
- C2N Diagnostics — Commercial assay validation
- Months 1-3: Sample collection and assay standardization
- Months 4-8: Discovery phase analysis
- Months 9-14: Validation phase
- Months 15-18: Machine learning model development
- Months 19-20: Final validation and clinical utility assessment
- Month 21-24: Manuscript and regulatory consultation
Total Duration: 24 months
- AUC >0.90 for preclinical AD detection
- Sensitivity >90% at 85% specificity
- Biomarker panel outperforms any single marker
- Progression prediction AUC >0.80
- Strong correlation with amyloid PET (r > 0.7)
- Cost-effectiveness demonstrated
- Clinical utility evidence for screening
- Pre-registration of analysis plan
- Blinded biomarker analysis
- Multi-center standardization
- Independent statistical review
| Dimension |
Score (1-10) |
Rationale |
| Scientific Value |
9 |
Enables early detection and understanding of AD |
| Feasibility |
8 |
Established assays and cohorts available |
| Novelty |
7 |
Builds on existing biomarker research |
| Disease Impact |
10 |
Transformative for early intervention |
| Reach |
10 |
Applicable to entire aging population |
| Cost Efficiency |
8 |
Low cost per person for screening |
| Time Efficiency |
7 |
24 months is standard for biomarker studies |
| Evidence Base |
8 |
Strong preliminary data from multiple groups |
| Addresses Uncertainty |
8 |
Validates clinical utility of blood biomarkers |
| Translation Potential |
10 |
Direct path to clinical implementation |
Total Score: 85 × weight normalization = 85/120